IMARC Group, a leading market research company, has recently releases report titled “Cancer Vaccines Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028.” The study provides a detailed analysis of the industry, including the global cancer vaccines market 2023 growth, share, size, trends, and forecasts. The report also includes competitor and regional analysis and highlights the latest advancements in the market.
How Big Is the Cancer Vaccines Market?
The global cancer vaccines market size reached US$ 6.1 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 12.1 Billion by 2028, exhibiting a growth rate (CAGR) of 11.61% during 2023-2028.
What is Cancer Vaccines?
Cancer vaccines are a unique category of immunotherapies that are designed to stimulate the immune system of the body to recognize and combat cancer cells. They work against specific tumor-associated antigens and encourage the immune system to target and eliminate malignant cells. They are widely available as preventive and therapeutic vaccines that minimize collateral damage to healthy cells. They reduce the risk of adverse effects commonly associated with conventional treatments. As they can be employed in conjunction with other treatments, such as chemotherapy, radiation therapy, and immunotherapies, the demand for cancer vaccines is rising across the globe.
Global Industry Trends and Drivers:
At present, the increasing preference for personalized treatment solutions among individuals around the world represents one of the primary factors propelling the market growth. Apart from this, the rising prevalence of various types of cancer among the masses across the globe is contributing to the market growth. In addition, the growing awareness about the importance of vaccines among individuals is offering a positive market outlook. Additionally, the rising adoption of cancer vaccines, as they offer an alternative to traditional therapies that may be associated with severe side effects, is offering lucrative growth opportunities to industry investors. Furthermore, the increasing emergence of advanced technologies, such as genetic engineering and immune checkpoint inhibitors, is strengthening the growth of the market.
What Is Included In Market Segmentation?
The report has been segmented the market into following categories:
Breakup by Type:
- Preventive Cancer Vaccines
- Therapeutic Cancer Vaccines
Breakup by Technology:
- Dendritic Cells Cancer Vaccines
- Recombinant Cancer Vaccines
- Antigen/Adjuvant Cancer Vaccines
- Viral Vector and DNA Cancer Vaccines
- Whole-cell Cancer Vaccines
Breakup by Indication:
- Cervical Cancer
- Prostate Cancer
- Others
Breakup by End User:
- Pediatrics
- Adults
Breakup by Region:
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
- Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
- Latin America
- Brazil
- Mexico
- Others
- Middle East and Africa
The report provides a comprehensive analysis of the industry key players listed below:
Anixa Biosciences Inc., Dendreon Pharmaceuticals LLC, Dynavax Technologies Corporation, GSK plc, Merck & Co. Inc., Moderna Inc., OSE Immunotherapeutics, Providence Therapeutics, Sanofi S.A., UbiVac Inc. and Vaccitech plc.
Comments